IGES Real World Evidence

Today, Real World Evidence (RWE) has advanced to the point where companies are increasingly considering its utility for managing their healthcare products throughout their lifecycle. Acceptance by regulators worldwide has increased, and payers are also increasingly turning to RWE to justify decisions about reimbursement of a healthcare product. RWE is being used to identify patient populations, more closely align studies with patient needs, size future markets, and generate evidence for regulators, payers, and patients. IGES can leverage its expertise with Real World Data in all of these areas. We have a multidisciplinary team that brings together the perspectives of RWE strategy, market access, epidemiology, biostatistics and data science, and clinical trials. Based on this, we can bring our clients' innovations to patients faster and in a more targeted way.

Our Services

IGES Pharma develops robust, flexible approaches to collecting, analyzing, and applying real-world data and insights.
Our strength is a deep understanding of the entire lifecycle of a medicinal product. This starts with strategic issues in market analysis and clinical trial design planning for the HTA process. We use real-world data across the spectrum of pharmaceuticals, medical devices, diagnostics and combination products. Our solutions are focused on safety, efficacy and value. We support you with:

  • Clinical trial design
  • Monitoring and data collection
  • Insights and recommendations on the use of real-world data in European HTA processes and innovative value-based reimbursement procedures.
  • New ways to generate evidence for pharmaceuticals.


Our 72-page guide “Reimbursement and Pricing of Pharmaceuticals in Europe” provides an overview of European pharmaceutical markets and explains the current regulatory, pricing and reimbursement systems of the five largest European countries: Germany, France, Italy, the United Kingdom and Spain.

If you would like a copy of the guide, please email Ms. Agata Daroszewska.